Topoisomerase inhibitors

9,210views

Topoisomerase inhibitors

before placement

before placement

Acyanotic congenital heart defects: Pathology review
Cyanotic congenital heart defects: Pathology review
Atherosclerosis and arteriosclerosis: Pathology review
Coronary artery disease: Pathology review
Peripheral artery disease: Pathology review
Valvular heart disease: Pathology review
Cardiomyopathies: Pathology review
Heart failure: Pathology review
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Aortic dissections and aneurysms: Pathology review
Pericardial disease: Pathology review
Endocarditis: Pathology review
Hypertension: Pathology review
Shock: Pathology review
Vasculitis: Pathology review
Cardiac and vascular tumors: Pathology review
Dyslipidemias: Pathology review
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Diabetes mellitus: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Diabetes insipidus and SIADH: Pathology review
Multiple endocrine neoplasia: Pathology review
Congenital gastrointestinal disorders: Pathology review
Esophageal disorders: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Inflammatory bowel disease: Pathology review
Malabsorption syndromes: Pathology review
Diverticular disease: Pathology review
Appendicitis: Pathology review
Gastrointestinal bleeding: Pathology review
Colorectal polyps and cancer: Pathology review
Pancreatitis: Pathology review
Gallbladder disorders: Pathology review
Jaundice: Pathology review
Viral hepatitis: Pathology review
Cirrhosis: Pathology review
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Pigmentation skin disorders: Pathology review
Acneiform skin disorders: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Vesiculobullous and desquamating skin disorders: Pathology review
Skin cancer: Pathology review
Back pain: Pathology review
Rheumatoid arthritis and osteoarthritis: Pathology review
Seronegative and septic arthritis: Pathology review
Gout and pseudogout: Pathology review
Systemic lupus erythematosus (SLE): Pathology review
Scleroderma: Pathology review
Sjogren syndrome: Pathology review
Bone disorders: Pathology review
Bone tumors: Pathology review
Myalgias and myositis: Pathology review
Neuromuscular junction disorders: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Congenital neurological disorders: Pathology review
Headaches: Pathology review
Seizures: Pathology review
Cerebral vascular disease: Pathology review
Traumatic brain injury: Pathology review
Spinal cord disorders: Pathology review
Dementia: Pathology review
Central nervous system infections: Pathology review
Movement disorders: Pathology review
Demyelinating disorders: Pathology review
Adult brain tumors: Pathology review
Pediatric brain tumors: Pathology review
Neurocutaneous disorders: Pathology review
Congenital renal disorders: Pathology review
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Acid-base disturbances: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Nephrotic syndromes: Pathology review
Nephritic syndromes: Pathology review
Urinary incontinence: Pathology review
Urinary tract infections: Pathology review
Kidney stones: Pathology review
Renal and urinary tract masses: Pathology review
Disorders of sex chromosomes: Pathology review
Prostate disorders and cancer: Pathology review
Testicular tumors: Pathology review
Uterine disorders: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Vaginal and vulvar disorders: Pathology review
Benign breast conditions: Pathology review
Breast cancer: Pathology review
Complications during pregnancy: Pathology review
Congenital TORCH infections: Pathology review
Choanal atresia
Laryngomalacia
Allergic rhinitis
Nasal polyps
Upper respiratory tract infection
Sinusitis
Laryngitis
Retropharyngeal and peritonsillar abscesses
Bacterial epiglottitis
Nasopharyngeal carcinoma
Respiratory distress syndrome: Pathology review
Cystic fibrosis: Pathology review
Pneumonia: Pathology review
Tuberculosis: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Obstructive lung diseases: Pathology review
Restrictive lung diseases: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Lung cancer and mesothelioma: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Valvular heart disease: Clinical
Infective endocarditis: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Hypothyroidism and thyroiditis: Clinical
Thyroid nodules and thyroid cancer: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal insufficiency: Clinical
Adrenal masses and tumors: Clinical
MEN syndromes: Clinical
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Peptic ulcers and stomach cancer: Clinical
Gastroparesis: Clinical
Diarrhea: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Colorectal cancer: Clinical
Diverticular disease: Clinical
Anal conditions: Clinical
Gastrointestinal bleeding: Clinical
Gallbladder disorders: Clinical
Pancreatitis: Clinical
Jaundice: Clinical
Viral hepatitis: Clinical
Cirrhosis: Clinical
Immunodeficiencies: Clinical
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Zinc deficiency and protein-energy malnutrition: Pathology review
Anemia: Clinical
Leukemia: Clinical
Thrombocytopenia: Clinical
Lymphoma: Clinical
Bleeding disorders: Clinical
Myeloproliferative neoplasms: Clinical
Thrombophilia: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Pneumonia: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Cystic fibrosis: Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Antihistamines for allergies
Glucocorticoids
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Loop diuretics
Antiplatelet medications
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Osmotic diuretics
Carbonic anhydrase inhibitors
Potassium sparing diuretics
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications

Transcript

Watch video only

Topoisomerase inhibitors, as their name implies, are a class of medications that act by blocking an enzyme called topoisomerase.

They are mainly used as anticancer agents that target specific phases of the cell cycle.

An interesting fact about these agents is that they are natural products, meaning they are extracted from roots, plants, or trees.

But first things first.

The cell cycle refers to the events that somatic cells - which includes all of the cells in our bodies except the reproductive cells - go through from the moment they’re formed until the moment they divide into two identical daughter cells.

This cycle varies in length depending on the type of cell.

For rapidly dividing cells, like skin cells, it takes less than a day, whereas for other cells, like liver cells, the cell cycle can last for years.

Now, the cell cycle can be divided into two phases: interphase and mitosis.

Interphase comprises of the G1 phase, during which the cell grows and performs its functions, the S phase, during which DNA is replicated, and the G2 phase, during which the cell grows again before entering mitosis, or the M phase.

Mitosis can be broken down into prophase, metaphase, anaphase, and telophase, during which the replicated DNA divides equally for the two daughter cells, and ends with cytokinesis, which is when the cell membrane actually divides to form the two new cells.

Okay, so during DNA replication, we unzip the double helix with the enzyme DNA helicase and this creates a replication fork, with the two prongs of the fork represented by the two strands that are separated from one another.

Now, as DNA helicase unzips the DNA, the segments of DNA ahead of it start to overwind - meaning, the double helix becomes more tightly wound.

Overwinding of the DNA can slow down replication, so the enzyme DNA topoisomerase works ahead of DNA helicase to loosen up the tight DNA coils.

It achieves this by gently snapping one strand, loosening the overwinding tension, and then patching it back up, tension free.

Okay, so topoisomerase inhibitors are meant to interfere with both types of DNA topoisomerases, called topoisomerase I and II.

Topoisomerase I cuts one of the two strands of the double-stranded DNA during replication, while Topoisomerase II cuts both strands.

If we disable these enzymes, DNA will overwind just like a rubber band, until it tears itself apart, leading to cell death.

Since cancer cells, in general, proliferate faster than healthy cells, they undergo DNA replication more frequently and are more prone to the DNA damage caused by topoisomerase inhibitors.

Alright, now topoisomerase inhibitors are cell cycle-specific, or CCS, agents, and they are the most active during the late S and early G2 phases of the cell cycle.

Okay, let’s start with camptothecins like irinotecan and topotecan, which are isolated from the stems of the Camptotheca tree, also called happy tree, cancer tree, or tree of life.

They bind to and inhibit topoisomerase I and cause DNA damage during replication, leading to cell death.

Irinotecan is a prodrug, meaning that it needs to be metabolized into an active form within the liver before it can produce the desired effect.

In terms of elimination, irinotecan is excreted through bile and feces, while topotecan is excreted through the kidneys, so the dose should be reduced in people with impaired renal function.

Now, irinotecan is used in metastatic colon cancer; and topotecan is used for the treatment of advanced ovarian cancer and for small cell lung cancer.

The two most common side effects are myelosuppression, or depression of the bone marrow function and gastrointestinal problems like diarrhea, which is more common with irinotecan, but in general, these medications have fewer toxicities than most other anticancer agents.

Alright, next we have the podophyllotoxins like etoposide and teniposide, which are derived from mandrake root, or Podophyllum peltatum.

These medications induce DNA breakage through the inhibition of topoisomerase II.

Elimination of teniposide and etoposide is mainly through the kidneys, which again means that the dosage needs to be reduced in people with renal problems.

Moving on to the indications, these agents are used in: solid tumors, particularly in testicular and small cell lung cancer; in leukemia, which is a type of blood cancer primarily affecting stem cells in the bone marrow; and in lymphomas, which usually derive from lymphocytes in the lymph nodes.

Key Takeaways

Topoisomerase inhibitors are a group of medications used in cancer chemotherapy that target the enzyme called DNA topoisomerase I or II, which is involved in DNA replication and transcription.

Topoisomerase inhibitors work by preventing the enzyme from unwinding DNA strands during replication or transcription, which leads to the accumulation of DNA damage and cell death. Examples include irinotecan and topotecan which inhibit topoisomerase I; and etoposide and teniposide which inhibit topoisomerase II.

Topoisomerase inhibitors are used to treat various types of cancer, such as colon cancer, leukemia, ovarian, and small-cell lung cancer. Common side effects of topoisomerase inhibitors include fatigue, gastrointestinal problems like diarrhea, hair loss, anemia, and increased risk of infection. Some patients may also experience more severe side effects, such as cardiac toxicity or secondary malignancies.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
  5. "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
  6. "Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules" Cancers (2018)
  7. "Formation and biological targets of botanical o-quinones" Food and Chemical Toxicology (2018)